FORT MYERS, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- American Oncology Network ("AON" or the "Company") (NASDAQ:AONC), one of the fastest growing community-based oncology practices, announced today that the Company will release its first quarter 2024 financial results on Wednesday, May 15, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on the same day. To access the call through a conference line, dial 1-877-704-44 ...

FORT MYERS, Fla., April 25, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (NASDAQ:AONC), one of the nation's fastest-growing community oncology networks, today launched its American Oncology Cares Foundation through its partner practices Hematology Oncology of Indiana in Indianapolis and Hope Cancer Care of Nevada in Las Vegas.  Non-medical expenses such as rent or mortgage, utilities, transportation costs and food qualify under the Foundation's essential living expenses requirement. Grant recipi ...

Core Insights - Central Georgia Cancer Care has partnered with the American Oncology Network (AON) to enhance patient care and services by leveraging AON's resources and expertise [1][2][3] - The partnership aims to provide additional essential patient services, including in-house pathology services and enhanced specialty pharmacy for oral oncolytic medication [2][3] - AON supports independent medical practices like Central Georgia Cancer Care to ensure they can continue delivering critical cancer care locally and affordably [3][4] Company Overview - Central Georgia Cancer Care has been providing high-quality, compassionate care to cancer and blood disorder patients since 1977, with a focus on innovative and effective treatment options [5] - The practice is recognized for its commitment to clinical trial participation and has received multiple certifications for high-quality cancer care, including QOPI® Certification and ASCO's Patient-Centered Cancer Care Certification [5] - AON, founded in 2018, represents over 240 providers across 21 states and focuses on value-based care to improve patient outcomes while reducing costs [4][5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 85-3984427 (State or other jurisdiction of incorporation o ...

American Oncology Network, Inc. (OTCQX:AONC) Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants Dave Gould - Chief Financial Officer Todd Schonherz - Chief Executive Officer Conference Call Participants Bill Sutherland - Benchmark Company Operator Good morning, and welcome to American Oncology Network's Fourth Quarter and Full Year 2023 Earnings Conference Call. Today's call is being recorded and we have allocated one hour for prepared remarks and Q&A. At this time, I would like ...

Exhibit 99.1 American Oncology Network, Inc. ("AON") Announces Fourth Quarter and Full Year 2023 Financial Results • Fiscal Year 2023 Revenue was $1,279.2 million, an 11.3% increase over 2022 o Patient encounter growth of 7.9% as compared to the prior fiscal year • Fourth Quarter 2023 Revenue was $324.2 million, a 7.9% increase over 2022 o Patient encounter growth of 9.5% as compared to the prior year quarter FORT MYERS, Fla., March 28, 2024 – American Oncology Network, Inc. (NASDAQ: AONC), a leading oncolo ...

FLORHAM PARK, N.J., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, announced today a partnership to advance the treatment of Waldenstrom's macroglobulinemia (WM) in the community setting with American Oncology Network (AON), a leading oncology platform with an innovative model of physician-led, community-based oncology manage ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-04321 American Oncology Network, Inc. (Exact name of registrant as specified in its charter) Delaware 85-3984427 (State or other jurisdiction of incorp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DIGITAL TRANSFORMATION OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) | --- | --- | --- | |------------------- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DIGITAL TRANSFORMATION OPPORTUNITIES CORP. (Exact name of registrant as specified in its charter) | --- | --- | --- | |------------------ ...